During the summer of 2011 rumors broke of a new and superior migraine medicine that should be 'imminent'.
A number of different types of migraine drugs are now being tested in clinical trials. Two of them are in what is called 'phase 3 clinical trials', ie. drug tested on a larger number of patients to find out if the medication is just as good or better than the 'gold standard' (here, sumatriptan), and whether there are serious adverse side effects.
Phase 3 trials are expensive, takes time and there is no guarantee that the results are good enough for approval of the drug. There are two drugs that might look promising.
Lasmiditan is a serotonin inhibitor, like triptans, but acts specifically on the receptors called 5HT1f, where triptans (also) affects 5HT1b and d-receptors, which contracts blood vessels. Lasmiditan have (therefore) not a vasoconstrictor effect, as it is known from the triptans. Lamiditan is tested in a Phase 3 trial in the latter half of 2011.
Telcagepant is a calcitonin gen-related peptide receptor (CGRP) antagonist. CGRP is a substance used to induce migraines experimentally because it dilates blood vessels. Telcagepant has been tested on women with menstrual migraine. The clinical trials werecompleted in May 2011, but the results are not published yet (last updated July 2011).
Lasmiditan is expected - possibly together with telcagepant - to generate a turnover in 2019 of 1.3 billion $ U.S. - especially since it is expected that the two will take over large parts of the market from Sumatriptan. see http://wraltechwire.com/business/tech_wire/medcity/story/9867615/
FDA publishes an updated list of what clinical trials are in progress. 17th July 2011 there were 392 trials in the list. The list is continually being updated.
< Back
A number of different types of migraine drugs are now being tested in clinical trials. Two of them are in what is called 'phase 3 clinical trials', ie. drug tested on a larger number of patients to find out if the medication is just as good or better than the 'gold standard' (here, sumatriptan), and whether there are serious adverse side effects.
Phase 3 trials are expensive, takes time and there is no guarantee that the results are good enough for approval of the drug. There are two drugs that might look promising.
Lasmiditan is a serotonin inhibitor, like triptans, but acts specifically on the receptors called 5HT1f, where triptans (also) affects 5HT1b and d-receptors, which contracts blood vessels. Lasmiditan have (therefore) not a vasoconstrictor effect, as it is known from the triptans. Lamiditan is tested in a Phase 3 trial in the latter half of 2011.
Telcagepant is a calcitonin gen-related peptide receptor (CGRP) antagonist. CGRP is a substance used to induce migraines experimentally because it dilates blood vessels. Telcagepant has been tested on women with menstrual migraine. The clinical trials werecompleted in May 2011, but the results are not published yet (last updated July 2011).
Lasmiditan is expected - possibly together with telcagepant - to generate a turnover in 2019 of 1.3 billion $ U.S. - especially since it is expected that the two will take over large parts of the market from Sumatriptan. see http://wraltechwire.com/business/tech_wire/medcity/story/9867615/
FDA publishes an updated list of what clinical trials are in progress. 17th July 2011 there were 392 trials in the list. The list is continually being updated.
| < Prev | Next > |
|---|
< Back
